The Goldman Sachs Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $36.00

Celldex Therapeutics (NASDAQ:CLDX) had its price objective cut by The Goldman Sachs Group from $42.00 to $36.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price would suggest a potential upside of 74.88% from the company’s previous close.

A number of other research firms have also commented on CLDX. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Friday. Finally, UBS Group began coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price target for the company. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $55.38.

Celldex Therapeutics Stock Up 0.1 %

Celldex Therapeutics stock traded up $0.02 during midday trading on Monday, hitting $20.59. 52,166 shares of the stock were exchanged, compared to its average volume of 896,325. Celldex Therapeutics has a 52 week low of $19.83 and a 52 week high of $53.18. The stock has a market capitalization of $1.37 billion, a PE ratio of -8.00 and a beta of 1.60. The company has a fifty day simple moving average of $23.86 and a two-hundred day simple moving average of $28.89.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. As a group, equities research analysts anticipate that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC increased its position in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 878 shares during the last quarter. KBC Group NV grew its stake in Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 495 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Celldex Therapeutics during the 4th quarter worth approximately $81,000. AlphaQuest LLC raised its stake in shares of Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,705 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at approximately $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.